Precision Medicine and PET–Computed Tomography in Pediatric Malignancies

Yasemin Sanli, Ebru Yilmaz, Rathan M. Subramaniam

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Fluorine-18 fluorodeoxyglucose (18F-FDG) PET–computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose 18F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT–based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine (131I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients. It may predict histologic differentiation and neoadjuvant therapy assessment in Wilms tumor.

Original languageEnglish (US)
Pages (from-to)423-435
Number of pages13
JournalPET Clinics
Issue number4
StatePublished - Oct 1 2017


  • Pediatric malignancies
  • PET
  • PET/CT

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Precision Medicine and PET–Computed Tomography in Pediatric Malignancies'. Together they form a unique fingerprint.

Cite this